Ludger Scheja

Ludger Scheja

Auto-generated profile, based on publicly available information

Ludger Scheja

Department of Biochemistry and Molecular Cell Biology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Molecular Metabolism
Verified
Journal Article
Open access
JHJörg Heeren
Jörg Heeren
LSLudger Scheja
Ludger Scheja
Non-alcoholic fatty liver disease, or as recently proposed 'metabolic-associated fatty liver disease' (MAFLD), is characterized by pathological accumulation of triglycerides and other lipids in hepatocytes. This common disease can progress from simple steatosis to steatohepatitis, and eventually end-stage liver diseases. MAFLD is closely related to disturbances in systemic energy metabolism, including insulin resistance and atherogenic dyslipidemia. The liver is the central organ in lipid metabolism by secreting very low density lipoproteins (VLDL) and, on the other hand, by internalizing fatty acids and lipoproteins. This review article discusses recent research addressing hepatic lipid synthesis, VLDL production, and lipoprotein internalization as well as the lipid exchange between adipose tissue and the liver in the context of MAFLD. Liver steatosis in MAFLD is triggered by excessive hepatic triglyceride synthesis utilizing fatty acids derived from white adipose tissue (WAT), de novo lipogenesis (DNL) and endocytosed remnants of triglyceride-rich lipoproteins. In consequence of high hepatic lipid content, VLDL secretion is enhanced, which is the primary cause of complex dyslipidemia typical for subjects with MAFLD. Interventions reducing VLDL secretory capacity attenuate dyslipidemia while they exacerbate MAFLD, indicating that the balance of lipid storage versus secretion in hepatocytes is a critical parameter determining disease outcome. Proof of concept studies have shown that promoting lipid storage and energy combustion in adipose tissues reduces hepatic lipid load and thus ameliorates MAFLD. Moreover, hepatocellular triglyceride synthesis from DNL and WAT-derived fatty acids can be targeted to treat MAFLD. However, more research is needed to understand how individual transporters, enzymes, and their isoforms affect steatosis and dyslipidemia in vivo, and whether these two aspects of MAFLD can be selectively treated. Processing of cholesterol-enriched lipoproteins appears less important for steatosis. It may, however, modulate inflammation and consequently MAFLD progression.

26 February 2013 in Nature Communications
Verified
Journal Article
Closed access
PDF file
LELeah Eissing
Leah Eissing
TSThomas Scherer
Thomas Scherer
KTKlaus Tödter
Klaus Tödter
UKUwe Knippschild
Uwe Knippschild
JGJan Willem Greve
Jan Willem Greve
LSLudger Scheja
Ludger Scheja

1 March 2016 in Cell Metabolism
Verified
Journal Article
Closed access
CSChristian Schlein
Christian Schlein
STSaswata Talukdar
Saswata Talukdar
MHMarkus Heine
Markus Heine
AFAlexander Fischer
Alexander Fischer
LKLucia M. Krott
Lucia M. Krott
LSLudger Scheja
Ludger Scheja

1 January 2021 in Cell Reports
Verified
Journal Article
Open access
CSChristian Schlein
Christian Schlein
AFAlexander Fischer
Alexander Fischer
FSFrederike Sass
Frederike Sass
AWAnna Worthmann
Anna Worthmann
KTKlaus Tödter
Klaus Tödter
LSLudger Scheja
Ludger Scheja
Thermoneutral conditions typical for standard human living environments result in brown adipose tissue (BAT) involution, characterized by decreased mitochondrial mass and increased lipid deposition. Low BAT activity is associated with poor metabolic health, and BAT reactivation may confer therapeutic potential. However, the molecular drivers of this BAT adaptive process in response to thermoneutrality remain enigmatic. Using metabolic and lipidomic approaches, we show that endogenous fatty acid synthesis, regulated by carbohydrate-response element-binding protein (ChREBP), is the central regulator of BAT involution. By transcriptional control of lipogenesis-related enzymes, ChREBP determines the abundance and composition of both storage and membrane lipids known to regulate organelle turnover and function. Notably, ChREBP deficiency and pharmacological inhibition of lipogenesis during thermoneutral adaptation preserved mitochondrial mass and thermogenic capacity of BAT independently of mitochondrial biogenesis. In conclusion, we establish lipogenesis as a potential therapeutic target to prevent loss of BAT thermogenic capacity as seen in adult humans.

17 January 2023 in Cells
Verified
Journal Article
Open access
PDF file
ILImke Liebold
Imke Liebold
SMSimon Meyer
Simon Meyer
MHMarkus Heine
Markus Heine
AKAnastasia Kuhl
Anastasia Kuhl
JWJennifer Witt
Jennifer Witt
AWAnna Worthmann
Anna Worthmann
Nonalcoholic fatty liver disease (NAFLD) is the most common liver pathology worldwide. In mice and humans, NAFLD progression is characterized by the appearance of TREM2-expressing macrophages in the liver. However, their mechanistic contributions to disease progression have not been completely elucidated. Here, we show that TREM2+ macrophages prevent the generation of a pro-inflammatory response elicited by LPS-laden lipoproteins in vitro. Further, Trem2 expression regulates bone-marrow-derived macrophages (BMDMs) and Kupffer cell capacity to phagocyte apoptotic cells in vitro, which is dependent on CD14 activation. In line with this, loss of Trem2 resulted in an increased pro-inflammatory response, which ultimately aggravated liver fibrosis in murine models of NAFLD. Similarly, in a human NAFLD cohort, plasma levels of TREM2 were increased and hepatic TREM2 expression was correlated with higher levels of liver triglycerides and the acquisition of a fibrotic gene signature. Altogether, our results suggest that TREM2+ macrophages have a protective function during the progression of NAFLD, as they are involved in the processing of pro-inflammatory lipoproteins and phagocytosis of apoptotic cells and, thereby, are critical contributors for the re-establishment of liver homeostasis.

5 December 2017 in Seminars in Immunopathology
Verified
Journal Article
Closed access
PDF file
MKManju Kumari
Manju Kumari
JHJoerg Heeren
Joerg Heeren
LSLudger Scheja
Ludger Scheja